Education
About Us
Working with TipRanks
Follow Us
Hua Medicine Ltd. (HK:2552)
:2552
Hm-002-1005
Diabetes Mellitus, Type Ii
Phase I
Completed
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
Apr 30, 2024
―
Empagliflozin, Dorzagliatin
Patients
Phase I
Completed
Drug Interaction Study Between Dorzagliatin and Empagliflozin
Dec 27, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Hua Medicine Ltd. (2552) have in its pipeline
2552 is currently developing the following drugs: Hm-002-1005, Empagliflozin, Dorzagliatin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.